person · Reporting owner
Wigzell Hans Lennart Rudolf
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | June 04, 2026 | June 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date June 04, 2026 · Filed June 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,098 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 16,875 · Balance 42,098 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 6, 2026 00:09 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 16,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-260259 · ownership.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,098 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Options (right to buy) · Derivative | 4,792 | $0.00 Strike: $99.69 | $0.00 |
DisclosureSEC source: 0000950170-25-037526 · ownership.xml · derivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,792 Underlying: Common Stock · 4,792 shares Expires 2035-03-10 Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,383 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-037526 · ownership.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,223 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 10, 2026. Read SEC document |
| December 12, 2024 Filed Dec 17, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Options (right to buy) · Derivative | 10,500 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0000950170-24-136847 · ownership.xml · derivative · entry 3 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2024 Filed Dec 17, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 10,500 | $124.84 | $1,310,820.00 |
DisclosureSEC source: 0000950170-24-136847 · ownership.xml · nonDerivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,840 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.92 to $124.80, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 12, 2024 Filed Dec 17, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 10,500 | $13.71 | $143,955.00 |
DisclosureSEC source: 0000950170-24-136847 · ownership.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 00:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0000950170-24-029536 · ownership.xml · derivative · entry 5 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2035-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 00:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 100 | $122.39 | $12,239.00 |
DisclosureSEC source: 0000950170-24-029536 · ownership.xml · nonDerivative · entry 4 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,840 Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 00:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 11,745 | $123.10 | $1,445,809.50 |
DisclosureSEC source: 0000950170-24-029536 · ownership.xml · nonDerivative · entry 3 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,940 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $122.65 to $123.58, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 00:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 3,155 | $123.85 | $390,746.75 |
DisclosureSEC source: 0000950170-24-029536 · ownership.xml · nonDerivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,685 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $123.6 to $124.6, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 00:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 15,000 | $13.90 | $208,500.00 |
DisclosureSEC source: 0000950170-24-029536 · ownership.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 3,679 | $0.00 Strike: $128.67 | $0.00 |
DisclosureSEC source: 0000950170-24-026619 · ownership.xml · derivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,679 Underlying: Common Stock · 3,679 shares Expires 2034-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026619 · ownership.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,840 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 1, 2025. Read SEC document |
| August 04, 2023 Filed Aug 9, 2023 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $29.03 | $0.00 |
DisclosureSEC source: 0001209191-23-045095 · doc4.xml · derivative · entry 3 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2023 Filed Aug 9, 2023 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 15,000 | $106.72 | $1,600,800.00 |
DisclosureSEC source: 0001209191-23-045095 · doc4.xml · nonDerivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,994 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.42 to $107.04 per share. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above. Read SEC document |
| August 04, 2023 Filed Aug 9, 2023 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 15,000 | $29.03 | $435,450.00 |
DisclosureSEC source: 0001209191-23-045095 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 3,257 | $0.00 Strike: $155.99 | $0.00 |
DisclosureSEC source: 0001209191-23-017404 · doc4.xml · derivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,257 Underlying: Common Stock · 3,257 shares Expires 2033-03-06 Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017404 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,994 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 6, 2024. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 5,077 | $0.00 Strike: $80.42 | $0.00 |
DisclosureSEC source: 0001209191-22-017350 · doc4.xml · derivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,077 Underlying: Common Stock · 5,077 shares Expires 2032-03-07 Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017350 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,471 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 7, 2023. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 01:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $34.92 | $0.00 |
DisclosureSEC source: 0001209191-21-019670 · doc4.xml · derivative · entry 3 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 01:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 10,000 | $83.51 | $835,100.00 |
DisclosureSEC source: 0001209191-21-019670 · doc4.xml · nonDerivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,518 F1 · price: The shares were sold in transactions at prices ranging from 83.33 to 83.91, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 01:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 10,000 | $34.92 | $349,200.00 |
DisclosureSEC source: 0001209191-21-019670 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:06 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 5,518 | $0.00 Strike: $87.11 | $0.00 |
DisclosureSEC source: 0001209191-21-018423 · doc4.xml · derivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,518 Underlying: Common Stock · 5,518 shares Expires 2031-03-03 Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:06 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018423 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,518 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $34.92 | $0.00 |
DisclosureSEC source: 0001209191-20-046251 · doc4.xml · derivative · entry 4 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2023-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 777 | $159.65 | $124,048.05 |
DisclosureSEC source: 0001209191-20-046251 · doc4.xml · nonDerivative · entry 3 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,792 F2 · price: The shares were sold in transactions at prices ranging from 159.47 to 159.90, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 9,223 | $158.95 | $1,465,995.85 |
DisclosureSEC source: 0001209191-20-046251 · doc4.xml · nonDerivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,569 F1 · price: The shares were sold in transactions at prices ranging from 158.45 to 159.36, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 10,000 | $34.92 | $349,200.00 |
DisclosureSEC source: 0001209191-20-046251 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Oprion (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.08 | $0.00 |
DisclosureSEC source: 0001209191-20-031881 · doc4.xml · derivative · entry 5 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 854 | $151.77 | $129,611.58 |
DisclosureSEC source: 0001209191-20-031881 · doc4.xml · nonDerivative · entry 4 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,792 F3 · price: The shares were sold in transactions at prices ranging from $151.67 to $151.75, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 2,046 | $151.22 | $309,396.12 |
DisclosureSEC source: 0001209191-20-031881 · doc4.xml · nonDerivative · entry 3 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,646 F2 · price: The shares were sold in transactions at prices ranging from $150.62 to $151.62, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 2,100 | $149.62 | $314,202.00 |
DisclosureSEC source: 0001209191-20-031881 · doc4.xml · nonDerivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,692 F1 · price: The shares were sold in transactions at prices ranging from $149.11 to $149.89, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 5,000 | $10.08 | $50,400.00 |
DisclosureSEC source: 0001209191-20-031881 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 5,000 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001209191-20-017097 · doc4.xml · derivative · entry 3 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 5,000 | $116.89 | $584,450.00 |
DisclosureSEC source: 0001209191-20-017097 · doc4.xml · nonDerivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,792 F1 · price: The shares were sold in multiple transactions at prices ranging from $116.8104 to $117.305, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 04, 2020 Filed Mar 7, 2020 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 5,000 | $8.46 | $42,300.00 |
DisclosureSEC source: 0001209191-20-017097 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 3,685 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014233 · doc4.xml · derivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,685 Underlying: Common Stock · 3,685 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:04 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 2,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014233 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,792 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-19-032833 · doc4.xml · derivative · entry 3 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option to purchase shares is fully vested. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 10,000 | $120.00 | $1,200,000.00 |
DisclosureSEC source: 0001209191-19-032833 · doc4.xml · nonDerivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,717 Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 10,000 | $7.80 | $78,000.00 |
DisclosureSEC source: 0001209191-19-032833 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 3,213 | $0.00 Strike: $145.48 | $0.00 |
DisclosureSEC source: 0001209191-19-016035 · doc4.xml · derivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,213 Underlying: Common Stock · 3,213 shares Expires 2029-03-04 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 01:05 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 1,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016035 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,717 F1 · shares: Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 6,667 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001209191-18-056987 · doc4.xml · derivative · entry 3 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires 2020-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option to purchase shares is fully vested. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 6,667 | $140.50 | $936,713.50 |
DisclosureSEC source: 0001209191-18-056987 · doc4.xml · nonDerivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,084 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $140.50 to $140.53, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the range set forth herein. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 22:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 6,667 | $8.94 | $59,602.98 |
DisclosureSEC source: 0001209191-18-056987 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:06 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 4,820 | $0.00 Strike: $71.45 | $0.00 |
DisclosureSEC source: 0001209191-18-017795 · doc4.xml · derivative · entry 2 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,820 Underlying: Common Stock · 4,820 shares Expires 2028-03-05 F2 · derivative.exercise_date: The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of the Issuer's 2018 Annual Meeting of Stockholders. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 23:06 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 3,418 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017795 · doc4.xml · nonDerivative · entry 1 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,084 F1 · shares: Each restricted stock award represents the right to receive one share of common stock and will vest in full on the first year anniversary of the Issuer's 2018 Annual Meeting of Stockholders. Read SEC document |
| November 30, 2017 Filed Dec 5, 2017 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 6,667 | $7.38 Strike: $7.38 | $49,202.46 |
DisclosureSEC source: 0001209191-17-063683 · doc4.xml · derivative · entry 3 Wigzell Hans Lennart Rudolf · CIK 0001492766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires 2018-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.87 to $55.93, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.